Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Prognostics

Background:

• Established prognostic models for diffuse large B-cell lymphoma (DLBCL), such as the International Prognostic Index (IPI) and National Comprehensive Cancer Network IPI (NCCN-IPI), have limitations.
• The prognostic role of beta-2 microglobulin (β2M) in DLBCL requires further elucidation.

Purpose of the Study:

• To evaluate the performance of existing DLBCL prognostic models, including those incorporating β2M.
• To develop and validate a novel prognostic model for DLBCL by integrating β2M with the NCCN-IPI.

Main Methods:

• Retrospective analysis of 6075 newly diagnosed DLBCL patients from the Danish Lymphoma Registry.
• Comparison of nine risk models, including NCCN-IPI and β2M-based models, using data from 3232 patients.
• Development of a new model, β2M-NCCN-IPI, by adding β2M to the NCCN-IPI.

Main Results:

• Models incorporating β2M and NCCN-IPI demonstrated superior discrimination compared to traditional IPI variants.
• Higher β2M levels correlated with inferior survival, advanced stage, and increased tumor burden.
• The novel β2M-NCCN-IPI model showed improved discriminatory ability (c-index 0.708) over NCCN-IPI (c-index 0.698).

Conclusions:

• Traditional IPI models, excluding NCCN-IPI, lack accuracy in risk stratification for DLBCL patients treated with rituximab.
• Beta-2 microglobulin (β2M) is a valuable, accessible biomarker that can enhance the prognostic performance of the NCCN-IPI.
• The β2M-NCCN-IPI model warrants further investigation for clinical application in DLBCL risk assessment.